BRAF and colorectal cancer: Tumors are subjected to immunohistochemistry (IHC) testing for MLH1, MSH2, MSH6, and PMS2. If MLH1 expression is absent, the tumor is then sequenced for presence of the BRAF V600E pathogenic variant, a common sporadic cause of colorectal cancer [16].